Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone
Table 2
Changes in metabolic parameters after 24 weeks of treatment.
12 weeks
24 weeks
Placebo group
29
28
RSG group
28
28
Body weight (kg)
Placebo group
<0.001
RSG group
BMI (kg/m2)
Placebo group
<0.001
RSG group
Systolic blood pressure, mmHg
Placebo group
0.083
RSG group
Diastolic blood pressure, mmHg
Placebo group
0.901
RSG group
HbA1c (%)
Placebo group
<0.001
RSG group
Fasting plasma glucose, mmol/L
Placebo group
<0.001
RSG group
Fasting plasma insulin, pmol/L
Placebo group
0.505
RSG group
Total cholesterol, mmol/L
Placebo group
<0.001
RSG group
Total triglyceride, mmol/L
Placebo group
0.822
RSG group
LDLc, mmol/L
Placebo group
<0.001
RSG group
HDLc, mmol/L
Placebo group
0.566
RSG group
HOMA2-%S
Placebo group
0.533
RSG group
HOMA2-%B
Placebo group
0.011
RSG group
HOMA-IR
Placebo group
0.197
RSG group
HOMA-
Placebo group
0.211
RSG group
Acid-labile subunit, mU/mL
Placebo group
0.627
RSG group
Each value represents the mean ± standard deviation (). values represent the between-group comparisons of the changes in the 12- and 24-week values from the baseline value. RSG: rosiglitazone; BMI: body mass index; HbA1c: hemoglobin A1c; LDLc: low-density lipoprotein cholesterol; HDLc: high-density lipoprotein cholesterol; HOMA2-%S: homeostatic model assessment version 2 insulin sensitivity; HOMA2-%B: homeostatic model assessment version 2 -cell function; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-: homeostatic model assessment of -cell function.